No Data
Xiangyu Medical (688626.SH): Suzhou Jifeng, Fuzhou Jifeng, and their concerted actors are no longer shareholders holding more than 5% of the company.
On December 17, 2024, Triumphant Medical (688626.SH) announced that it received a "Simplified Equity Change Report" from Suzhou Jifeng, Fuzhou Jifeng, and Jiaxing Jifeng No. 1. From December 9 to December 16, 2024, Suzhou Jifeng and Fuzhou Jifeng reduced their shareholdings in the company through centralized bidding trading, totaling 400,200 shares, accounting for 0.250125% of the company's total share capital. After this equity change, Suzhou Jifeng, Fuzhou Jifeng, and their concerted action party Jiaxing Jifeng No. 1 together hold 7,999,920 shares of the company.
Xiangyu Medical (688626.SH): The Shareholders and their concerted acting persons' total shareholding ratio has fallen below 5%.
On December 17, Gelonghui reported that Xiangyu Medical (688626.SH) announced that shareholders Suzhou Jifeng, Fuzhou Jifeng, and their concerted party Jiaxing Jifeng No. 1, due to their own financial needs, cumulatively reduced their Shareholding in the company by 400,200 shares through centralized bidding trade, accounting for 0.250125% of the company's total equity. After this change in rights and interests, the aforementioned shareholders hold a total of 7,999,920 shares in the company, constituting 4.99995% of the company's total equity, and are no longer shareholders holding more than 5% of the company.
Xiangyu Medical Co.,Ltd's (SHSE:688626) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Xiangyu Medical (688626.SH): The layout in the brain-computer interface is primarily focused on mental psychology, EEG collection devices, proactive training, and other directions.
On December 5, Gelonghui reported that Xiangyu Medical (688626.SH) stated on the interaction platform that the company is focusing on the brain-computer interface area with directions including mental health, EEG collection devices, and active training, with multiple products already entering the registration process. Mental health-related products are expected to meet sales conditions as early as this year, active training products are anticipated to obtain registration certification next year, and EEG collection devices are expected to receive registration certification in the first half of next year.
Xiangyu Medical (688626.SH): First-time repurchase of 0.1058 million shares.
On November 26, Gelunhui reported that Xiangyu Medical (688626.SH) announced that on November 26, 2024, the company repurchased 105,800 shares of the company for the first time through the Shanghai Stock Exchange trading system using centralized bidding trading method, accounting for 0.0661% of the company's total share capital of 160,000,000 shares. The highest price of the repurchase transaction was 31.20 yuan/share, the lowest price was 30.80 yuan/share, and the total amount paid was 3,271,257.28 yuan (excluding transaction fees such as trading commissions and transfer fees).
The delay in bidding at the hospital end has negatively impacted revenue. Xiangyu Medical is cultivating a second growth curve, with brain-machine products expected to be available for sale as early as this year.
① Due to delays in the bidding activities at the hospital level, Xiangyu Medical experienced a decline in revenue in the first three quarters of 2024. The company is increasing its marketing efforts in areas such as military, exports, home care, private health care, and off-site services; ② Xiangyu Medical's layout in brain-computer interfaces is mainly focused on non-invasive rehabilitation devices, with mental health products expected to be market-ready as early as this year.
Investors Aren't Buying Xiangyu Medical Co.,Ltd's (SHSE:688626) Earnings
